BRUSSELS--(BUSINESS WIRE)--At this year’s Bio International Convention, e-health company Esperity will be introducing its ground-breaking social media network designed to help cancer patients manage their health better, while connecting and sharing information with other patients worldwide.
Due for launch later this year, Esperity’s online solution is currently being validated by trial users and experts, including Stanford University, John Hopkins University and the Bordet Institute in Brussels. It is also gaining widespread interest from patient groups, healthcare professionals and pharmaceutical companies. Founded by the same team behind award-winning CPD patient site MiMedication, Esperity was runner-up at the Eurotech Pitch Competition, November 2012.
Says CEO and co-founder Mitchell Silva: “Esperity fills a market need. It gives cancer patients a simple way to monitor symptoms and manage medication, while connecting with other patients worldwide, so they can share information and feel less alone. It will also create a unique knowledge base that will be useful to both patients and healthcare professionals. Esperity is unique: as well as being the only dedicated global social media networks for cancer patients, it supports over 30 languages.”
“Esperity also provides healthcare and pharmaceutical organisations a way to add value to how they support patients, for instance as an addition to patient adherence programmes. Esperity is a great complement to the work that the healthcare community is already doing.”
Key features include: monitoring patterns, the disease’s progression, drug interactions, or side effects to help patients manage their healthcare better, plus reminder alerts to take the right medication at the right time. Information can remain private, but patients can choose to share selected data with the Esperity network, to help create a global knowledge base. Esperity also enables patients to ‘twin’ with people suffering from the same cancer, anywhere in the world, in much the same way that people connect on Facebook.
Says Mitchell Silva, “Cancer patients often have limited time with medical specialists and can feel isolated. Esperity provides patients with a way to help themselves and potentially improve quality of life.”
Experienced entrepreneur Mitchell was inspired to become an e-health innovator based on his own experience as a CPD patient. He holds a PhD degree in bioscience engineering, while co-founder Erard le Beau de Hemricourt is a MD specializing in nuclear medicine and has worked closely with cancer patients. Esperity is based in Brussels, Belgium. www.esperity.com